Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Addict Med. 2020 Sep-Oct;14(5):e188–e194. doi: 10.1097/ADM.0000000000000630

Table 2.

Model estimated main effects from logistic regression models of aim 1

Among all participants (n=1241)
Aim 1 Outcome: Retained at Week 24
Effect b SE p OR (95% CI)
Covariates:
Age 0.031 0.006 <.001 1.032 (1.019, 1.044)
Gender (ref=Female) 0.000 0.137 0.999 1.000 (0.764, 1.309)
Hispanic (ref=No) −0.353 0.176 0.044 0.702 (0.498, 0.991)
Maximum Dose (ref=Low) 1.383 0.141 <.001 3.988 (3.023, 5.263)
Predictors:
Treatment (ref=Buprenorphine) 1.152 0.133 <.001 3.166 (2.438, 4.111)
Baseline Pain (ref=No Pain) 0.109 0.128 0.398 1.115 (0.866, 1.434)
Pain Improvement at week 4 (ref=No) -- -- -- -- --

-- Refers to variables not relevant to the model